Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT06933069
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 336
- Registration Number
- NCT06398652
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 392
- Registration Number
- NCT06365879
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Post-change CMAB807
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 128
- Registration Number
- NCT06361355
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT05906576
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: XolairBiological: CMAB007
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 114
- Registration Number
- NCT05897008
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers
Phase 1
Withdrawn
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Xgeva®Biological: Post-change CMAB807XBiological: Pre-change CMAB807X
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Registration Number
- NCT05808673
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Secukinumab
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 130
- Registration Number
- NCT05734482
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT04779892
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 114
- Registration Number
- NCT04778137
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath